Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 230

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma

Open access
Pinnix, Chelsea C., Gunther, Jillian R., Dabaja, Bouthaina S., Strati, Paolo, Fang, Penny, Hawkins, Misha C., Adkins, Sherry, Westin, Jason, Ahmed, Sairah, Fayad, Luis, Lee, Hun Ju, Nair, Ranjit, Steiner, Raphael E., Iyer, Swaminathan P., Rodriguez, M. Alma, Wang, Michael, Flowers, Christopher, Neelapu, Sattva S., Nastoupil, Loretta J. · 2020 · Blood Advances

Abstract

The impact of bridging therapy (BT) administered between leukapheresis and chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is unclear. We evaluated the influence of BT (systemic therapy [ST], radiation therapy [RT], or combined-modality therapy [CMT]) on outcomes of 148 LBCL patients who underwent leukapheresis for planned axicabtagene ciloleucel (axi-cel) infusion. The 55% (n = 81) of patients who received BT were more likely to have international prognostic index (IPI) score ≥3 (P ≤ .01), bulky disease (P = .01), and elevated lactate dehydrogenase (LDH; P ≤ .01). The 1-year progression-free (PFS) and overall survival (OS) rates were 40% and 65% in non-BT patients vs 21% and 48% in BT patients (P = .01 and .05, respectively). Twenty-four patients (16%) did not receive axi-cel, most commonly because of lymphoma progression (88%), despite 80% (n = 19) receiving BT. Among 124 patients who received axi-cel, 50% (n = 62) received BT with ST (n = 45), RT (n = 11), or CMT (n = 6); 1-year PFS and OS rates were not significantly different between BT and non-BT cohorts (P = .06 and .21, respectively). There was no difference in proportion of patients with IPI ≥3, limited-stage disease, or elevated LDH between ST, RT, and CMT groups. Compared with non-BT patients, 1-year PFS was inferior for ST-bridged patients (P = .01). RT-bridged patients had improved PFS compared with ST-bridged patients (P = .05). Despite the poor prognosis associated with requiring BT, RT can be an effective bridging strategy. Future studies are necessary to identify strategies that may improve access to CAR T-cell therapy and outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2020001837

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 230

Metadata

Authors
Pinnix, C. C., Gunther, J. R., Dabaja, B. S., Strati, P., Fang, P., Hawkins, M. C., Adkins, S., Westin, J., Ahmed, S., Fayad, L., Lee, H. J., Nair, R., Steiner, R. E., Iyer, S. P., Rodriguez, M. A., Wang, M., Flowers, C., Neelapu, S. S., & Nastoupil, L. J.
Venue
Blood Advances
Published
2020-06-26
Volume
4
Issue
13
Pages
2871-2883
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
OpenAlex
W3037322433
Cited by
230
References
5
FWCI
10.59
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. https://app.cochat.ai/papers/10.1182/bloodadvances.2020001837
The paper
Pinnix, C. C., Gunther, J. R., Dabaja, B. S., Strati, P., Fang, P., Hawkins, M. C., Adkins, S., Westin, J., Ahmed, S., Fayad, L., Lee, H. J., Nair, R., Steiner, R. E., Iyer, S. P., Rodriguez, M. A., Wang, M., Flowers, C., Neelapu, S. S., & Nastoupil, L. J. (2020). Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Advances. https://doi.org/10.1182/bloodadvances.2020001837

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.